Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dry Eye Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

NCT06964269
View directory record Official record
Conditions
Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

NCT01632527
View directory record Official record
Conditions
Age Related Macular Degeneration, Macular Degeneration, AMD
Interventions
HuCNS-SC cells
Drug
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2015 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional

Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion

NCT00735865
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Punctal plugs, punctal cautery, Punctal Plug, Punctal thermocauterization, Silicone plug or thermodynamic hydrophobic acrylic plug, Previous subjects with Punctal occlusion
Procedure · Other
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Burlington, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2009 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 4 Interventional

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Procedure · Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

NCT04362670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OTX-CSI, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression

NCT05713981
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Meibomian gland (MG) expression
Procedure
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients

NCT04590196
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Longvida curcumin, placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2Phase 3 Interventional

Study of TOP1630 for Dry Eye Syndrome

NCT03833388
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Drug
Lead sponsor
Topivert Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Lewiston, Maine • Andover, Massachusetts • Raynham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 21, 2026, 7:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users

NCT05306561
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Systane iLux thermal pulsation treatment
Procedure
Lead sponsor
Periman Eye Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops

NCT00610480
View directory record Official record
Conditions
Dry Eye Disease
Interventions
1st visit Optive, then 2nd visit Systane, 1st visit Systane, then 2nd visit Optive
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 4 Interventional

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

NCT03451396
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

NCT03916042
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 21, 2026, 7:11 AM EDT
Active, not recruiting Phase 3 Interventional

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
43
States / cities
Chula Vista, California • Fullerton, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

NCT03226769
View directory record Official record
Conditions
Meibomian Glands, Dry Eye Syndromes
Interventions
TrueTear™, Thermalon Dry Eye Compress
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 21, 2026, 7:11 AM EDT
Not yet recruiting No phase listed Observational

Lacrifill for Ocular Surface Optimization in Cataract Surgery

NCT07648095
View directory record Official record
Conditions
Cataract
Interventions
Lacrifill Canalicular Filler
Device
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
40 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Break-up Time After Instillation of Artificial Tears

NCT00681265
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
glycerin, polyethylene glycol 400/propylene glycol
Drug
Lead sponsor
Calm Water Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Jul 21, 2026, 7:11 AM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2 Interventional Results available

ESBA105 in Patients With Severe Dry Eye

NCT01338610
View directory record Official record
Conditions
Eyes Dry Chronic
Interventions
ESBA105 ophthalmic solution, ESBA105 vehicle
Biological · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Jul 21, 2026, 7:11 AM EDT
Not listed Not applicable Interventional

Senofilcon A Lenses in Moderate to Severe Dry Eye Disease

NCT04096898
View directory record Official record
Conditions
Moderate to Severe Dry Eye Disease
Interventions
Senofilcon A contact lens
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

NCT01128049
View directory record Official record
Conditions
Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
Interventions
Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop
Behavioral · Procedure · Drug
Lead sponsor
University of Rochester
Other
Eligibility
20 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 21, 2026, 7:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Natural History Study of Patients With Dry Eye

NCT00833235
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial Tears
Other
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
17
States / cities
Little Rock, Arkansas • Mission Hills, California • Rancho Mirage, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 21, 2026, 7:11 AM EDT